BUSINESS STRATEGY Novartis difference puts

First Page		Document Content
Date: 2013-11-20 09:24:38 Novartis Sandoz Hospira Biosimilar Mylan Alcon Food and Drug Administration Pharmaceutical industry Pharmaceutical sciences Pharmacology		BUSINESS STRATEGY Novartis difference puts Add to Reading List Source URL: www.generics-bulletin.com Download Document from Source Website File Size: 131,41 KB Share Document on Facebook

	BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi DocID: 1rrNB - View Document
	ZAI Lab announces appointment of Dr. James Yan as Executive Vice President of Early Development and Drug Safety Shanghai, China – October – Zai Lab Limited (Zai Lab), an innovative biotech company based in Ch DocID: 1qDbm - View Document
	United States Court of Appeals for the Federal Circuit ______________________ THE MEDICINES COMPANY, Plaintiff-Appellant DocID: 1qAvA - View Document
	April 29, Sanofi Rebuffed in $9.3 Billion Proposal to Acquire Medivation Sanofi has made a nonbinding proposal to acquire Medivation, Inc., a San Franciscobased biopharmaceutical company, for DocID: 1q9zg - View Document
	Products Approved in FY 2010: New Drugs Review Approval Date No. Category Brand Name DocID: 1pe3I - View Document